Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Otavio Berwanger and Anna Langkilde.
Otavio Berwanger
Connection Strength
0.297
Anna Langkilde
  1. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 09; 9(9):586-594.
    View in: PubMed
    Score: 0.239
  2. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. Diabetes Obes Metab. 2021 04; 23(4):886-896.
    View in: PubMed
    Score: 0.058
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.